Please login to the form below
Alessandro Riva
This page shows the latest Alessandro Riva news and features for those working in and with pharma, biotech and healthcare.
Riva leaves Gilead to head Glenmark’s innovation spin-off
Company has own bispecific antibody platform. Indian pharma company Glenmark has appointed Alessandro Riva as the chief executive of its new spin-off company focused on innovative medicines. ... In a statement, Riva said he was excited to join a company
Latest news
-
Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
Alessandro Riva, MD, Gilead's executive vice president, Oncology Therapeutics &Head, Cell Therapy said: “This research collaboration adds an additional new platform to our current capabilities in research and cell manufacturing,
-
Novartis seeks first-line use for lung cancer drug Zykadia
Zykadia has proven to be an important treatment option for ALK+ NSCLC patients who have progressed following treatment with crizotinib," said Novartis head of oncology development and medical affairs, Alessandro Riva.
-
Novartis claims FDA breakthrough status for leukaemia treatment
established. Alessandro Riva, managing director and global head for Novartis' oncology development and medical affairs, said: “For more than 25 years, medical developments have been limited for AML patients and the
-
FDA needs more time to review Novartis’ cancer drug
Alessandro Riva, global head of oncology development and medical affairs for Novartis's oncology business, said: "We are committed to working with the FDA as they continue to review the LBH589
-
Novartis plans filings for acromegaly candidate
Alessandro Riva, interim president of Novartis Oncology and global head of oncology development and medical affairs, said: "These results strengthen our understanding of this rare endocrine disorder and suggest pasireotide LAR
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics
Gilead Sciences has promoted Dr Alessandro River from senior vice president, haematology and oncology therapeutic area head, to executive vice president, oncology therapeutics. ... Dr Riva joined the biopharmaceutical group in January 2017, and his
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
B2B media account director
-
Competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- What is EVID AI?
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- AstraZeneca and Ionis sign $3.6bn deal for eplontersen
- Roche’s Actemra approved for severe COVID-19 in Europe
- Mix-and-match COVID-19 vaccines may be more effective
- Keytruda gains eighth FDA approval this year
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Sanofi to buy acne specialist Origimm
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Promoting off-label use: where to draw the line?
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
ahair@onyxhealth.com
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- ...
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
